Global Farber’s Disease Market Insight, Epidemiology and Market Forecast to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Farber’s Disease – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This ‘Farber’s disease – Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the Farber’s disease, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Farber’s disease market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Farber’s disease market Size from 2017 to 2030 segmented by seven major markets. The report also covers current Farber’s disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Farber’s disease Epidemiology

The Farber’s disease symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Farber’s disease epidemiology segmented as the total diagnosed prevalent cases of Farber’s disease, gender-specific cases of Farber’s disease, and type-specific cases of Farber’s disease.

Farber’s disease Emerging Drugs

RVT-801 (Enzyvant) is a recombinant form of human acid ceramidase (rhAC) being developed as a potential enzyme replacement therapy for acid ceramidase deficiency, manifesting as Farber disease. It is being evaluated in preclinical studies to enable a clinical trial in patients with Farber disease. The company plans to commence clinical trials by 2020 at eight sites across seven countries participating in the study. (Read more…) RVT-801 was granted Rare Pediatric Disease, Fast Track designations. The drug has also received Orphan Drug designations by the FDA and EMA.

Farber’s disease Market Outlook

The Farber’s disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Farber’s disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Farber’s disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Farber’s disease market in the 7MM is expected to change in the study period 2017-2030.

The management and diagnosis of FD have not advanced significantly in the past decade, but given recent advances in understanding the timing and potential pathogenesis of FD, it is hopeful that the next decade will bring early diagnostics and novel therapeutics.

Key Topics Covered:

1. Key Insights

2. Farber Disease: Market Overview at a Glance

2.1. Market Share (%) Distribution of Farber Disease in 2017

2.2. Market Share (%) Distribution of Farber Disease in 2030

3. Organizations

4. Executive Summary

5. Disease Overview: Farber Disease

5.1. Introduction

5.2. Classification

5.3. Signs and Symptoms

5.4. Clinical manifestations

5.5. Pathophysiology

5.6. Diagnosis

5.6.1. Differential Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent Population of Farber Disease in 7MM

7. 7MM Epidemiology of Farber Disease

7.1. Assumptions and Rationale

7.2. United States

7.2.1. Total Diagnosed Prevalent cases of Farber Disease in the US

7.2.2. Gender-specific cases of Farber Disease in the US

7.2.3. Type-specific cases of Farber Disease in the US

7.3. Germany

7.4. France

7.5. Italy

7.6. Spain

7.7. The UK

7.8. Japan

8. Treatment and Management

9. Unmet Needs

10. Emerging Therapies

10.1. RVT-801: Enzyvant

10.1.1. Drug Description

10.1.2. Other development activity

10.1.3. Safety and Efficacy

10.1.4. Product Profile

11. Farber Disease: 7 Major Market Analysis

11.1. Key Findings

11.2. Market Size of Farber Disease in the 7MM

12. Market Outlook: 7MM

13. Market Drivers

14. Market Barriers

15. Market Access and Reimbursement

16. SWOT Analysis

17. Case Studies

17.1. Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report

17.2. Farber Disease Misdiagnosed as Hemangioendothelioma

18. KOL views

19. Bibliography

20. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2p7jcz

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900